Along with Johnson’s failure, there are also winners – Moderna and Pfizer are expected to capture high market share at Johnson’s expense and investors are soaring stocks – Modern at 10%, Pfizer at 3%.
Pfizer and Modernana vaccines are based on the mRNA molecule. The Johnson & Johnson vaccine uses corona virus DNA, and is given in just one dose and not two. The effectiveness rate of the vaccines developed by Pfizer and Moderna is higher – about 95%.
Johnson & Johnson said it will submit the vaccine to the U.S. Food and Drug Administration (FDA) for emergency approval next week, and is expected to begin vaccinations in early February.
Update on vaccine efficacy:
Following Moderna’s announcement that its vaccine is relatively weak against the South African mutation, last night Pfizer also announced that the vaccine works, but less effectively.
Modern’s vaccine, it will be recalled, is also weaker against the South African virus – Expansion here. At the same time, Eli Lilly reported that in her experiment, antibodies created from Pfizer and Modernena vaccines were found to be less effective against the South African mutation, which shows much higher resistance than the initial version of the corona virus.
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment